Recursion
A clinical-stage drug developer that runs automated experiments on cells at scale and uses the data and AI models to find and design drug candidates, for its own pipeline and for partners including Sanofi and Roche.
Listed on Nasdaq as RXRX since its IPO closed on 16 April 2021, by the company's own timeline.
Money and evidence
Latest round, Follow-on offering, 2026-10-15: the record then held 1 research entry, highest level 5. The first research entry is dated 2026-10-15; the highest level so far is 5 (Used in practice).
Rounds and research, on one timeline
- 2026-11-02Research
Level 5 · Used in practice
Recursion reports REC-4881 cut polyp burden by a median 47% in 15 patients with an inherited polyp disease, and 11 of 13 stayed below baseline 12 weeks
after stopping FAP has no approved drug: patients are managed with repeated endoscopy and surgery, and Recursion puts the market at $15B by its own estimate. The company says a phenotypic screen run with its AI foundation models found that blocking MEK1/2 could reverse the cell effects of losing APC, the gene behind FAP, so the trial tests whether a link its platform found in cells holds in patients. It plans a registrational trial in the second half of 2027, pending talks with the FDA, and has not yet given its design.
- 2026-10-15Research
Level 5 · Used in practice
Recursion reports three partial responses among 12 patients on REC-1245, a cancer drug whose target and molecule it says both came from
its platform Recursion says its platform contributed all three core elements of this programme: the target (degrading RBM39 mimics losing CDK12), the molecule and the first guess at which patients would benefit. Chief executive Najat Khan called it an early example of the whole engine working inside one programme. For partners and investors, that is the claim the platform is sold on, and it now has a small number of patients behind it. Expansion data in endometrial cancer are due in the second half of 2027.
- 2026-10-15Follow-on offeringRound
$200M
For: Operating needs; with this offering the company expects its cash to last into 2029
Not stated
61.54 million Class A shares at $3.25, closed 16 October; net proceeds about $187.2M (the Q3 release). Buyers as named in the company's release of the same day.
AdageARKDriehausInvusJanus Henderson Investors
Advisers: Leerink Partners (representative of the underwriters); Goldman Sachs (representative of the underwriters); Morgan Stanley (representative of the underwriters); Evercore (representative of the underwriters)
By this date the record held 1 research entry, highest level 5
- 2021-04-16IPORound
not disclosed on the company page
Not stated
No investor named in the source.
- 2020-09-09Series D
- 2019-02-12Series CRound
not disclosed on the company page
Not stated
- 2017-09-25Series BRound
not disclosed on the company page
Not stated
- 2016-09-02Series ARound
not disclosed on the company page
Not stated
Lead · Baillie Gifford
Lead · DCVC
Lead · Lux CapitalResearch entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Lux CapitalWarp Sciences, Transfyr, Xaira Therapeutics, EvolutionaryScale, Enveda, Medra, CuspAI, LabGenius, Multiply Labs
- DCVCChai Discovery, Noetik, Relation Therapeutics
- Baillie GiffordChai Discovery, Enveda
- ARKIambic Therapeutics, Lila Sciences
- InvusMatchpoint Therapeutics